杜皮卢马布治疗COPD的2型炎症,以乙氨基酸细胞计数为指标

Surya P Bhatt¹, Klaus F Rabe¹, Nicola A Hanania¹+20

• ¹From the Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham (S.P.B.); LungenClinic Grosshansdorf and Christian Albrechts University of Kiel, Airway Research Center North, German Center for Lung Research, Grosshansdorf (K.F.R.), and the Department of Medicine, Pulmonary, and Critical Care Medicine, University of Marburg, German Center for Lung Research, Marburg (C.F.V.) - all in Germany; the Department of Medicine, Section on Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston (N.A.H.); OK Clinical Research, Edmond, OK (J.C.); King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London (M.B.), and Manchester University NHS Foundation Trust, University of Manchester, Manchester (D.S.) - both in the United Kingdom; the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, San Francisco (S.A.C.); the University of Ferrara, Ferrara, Italy (A.P.); Sanofi, Bridgewater, NJ (E.L., H.W.S., X.L., D.B.); Sanofi, Chilly-Mazarin, France (L.P.M.); Sanofi, Cambridge, MA (N.P., L.B.R., R.M.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (G.D.Y., E.R.M., B.A., J.M., A.B.).